Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Approves First Next-Generation DNA Sequencing Platforms

This article was originally published in The Gray Sheet

Executive Summary

Illumina’s MiSeqDx instrument and MiSeqDx Universal Kit, granted de novo approval, allow clinicians to “develop and validate sequencing of any part of a patient’s genome,” FDA says.


Related Content

Q&A: FDA Dx Reviewer's Tips For Next-Gen Sequencing Sponsors
Classified: Next-Gen Sequencing Analyzers, Mobile Glucose Monitoring, Restless-Leg Devices
US FDA's Next-Gen Sequencing Guidances: One Stop On A Pathway
Illumina Aims For All-Inclusive Cancer Screen Via New Start-Up
Research Group Urges Standards For Curated Genetic Databases
Experts Criticize FDA's Plan To Regulate Genomic Tests
Lung Cancer “Master Protocol” Eyed As Paradigm-Changing Approach To Drug Development
FDA’s Upcoming Drug/Diagnostic Co-Development Guidance Could Quickly Become Outdated
Lawmakers Press OMB To Release Lab-Developed Test Draft Guidance
Human Genome Research Led To $65 Billion In Economic Output In 2012, Says Battelle Report


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts